Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
BioIndustry Association: Nigel Gaymond




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: BioIndustry Association: Nigel Gaymond
Released on: March 09, 2011. © PharmaTelevision Ltd
Visitors: You are watching a 5 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks to Nigel Gaymond, CEO of BioIndustry Association
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Primary role of BioIndustry Association
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here in Munich at BIO-Europe 2010. On this show I have Nigel Gaymond , who is the Chief Executive of the BioIndustry Association based in the UK, welcome to the show.
Nigel Gaymond :
Thank you.
Fintan Walton:
Nigel Gaymond , the BioIndustry Association or the BIA is obviously an important association industry association for biotechnology companies in the UK, what would you say is the primary role or goal even of BIA ?
Nigel Gaymond :
Well I think it changes I mean it's been in existence for 21-years now, I am effectively the 5th CEO, I actually interfaced with it back in 1989 when it was formed when I was working in Boston. I think it's role has changed it has been very good on the lobbying side and sort of focusing a bit more on the ecosystem if you like in terms of what the UK is and should be, so it's a dual-purpose.
Fintan Walton:
Right, so when you talk about the echo system you are talking about presumably largely the financial conditions which enable biotechnology to thrive?
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Nigel Gaymond
CEO
Nigel Gaymond joined the BioIndustry Association (BIA) in January 2010 as Chief Executive. Prior to joining the BIA , Nigel Gaymond provided consultancy services to a range of life sciences companies in the USA and Europe through his consulting practice, Gaymond International, focusing on the life sciences biotechnology, medical device/technology, pharmaceutical, veterinary health, and Ag/bio. He has also worked as a Managing Partner at the healthcare and technology development company Mosaigen and as Director of Corporate Development for the corporate transaction adviser Tranziger. Previously, Nigel Gaymond served for nearly seven years as a Commercial Officer at the British Consulate-General in Boston, Massachusetts, where he ran the Commercial Department in assisting the UK's biotechnology, healthcare and agriculture exports and became the British government's lead Commercial Officer for biotechnology in the US. He was also the founding CEO of the Edinburgh BioAlliance in Scotland, has been a special adviser to the Invest in Sweden Agency in North America; operated BELS (British Expats in Life Sciences), a network that linked the hundreds of ex-patriate "Brits" working in the life sciences in North America; and published SN(i)PS, a subscription weekly life sciences news digest. Before moving to the US in 1985 for his role at the British Consulate-General, Nigel Gaymond spent some time in sales and marketing at IBM in the UK, having started his working life as a teacher. Currently, Nigel Gaymond is on the Board of Trustees of The Forsyth Institute in the US, the leading independent dental and craniofacial research organization in the world, where he is involved in various business development activities. Nigel Gaymond also chairs the US Business Advisory Board of the Child Health Research Institute doing business as CureKids, and was a member of the North American board of the New Zealand Beachheads program, chairing its Life Science panel of advisors, and having now moved over to the UK Board of this programme. Previously he served on the boards of the Scottish BioNetwork Association, the British American Business Council of New England and the New England Chapter of the British Olympic Association. Nigel Gaymond is a former first class rugby player in the UK who played on two national championship teams and also was a semi-professional jazz musician in his younger days. Nigel Gaymond has a BSc in Linguistic and International Studies from the University of Surrey, and a post-graduate degree in Education.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
BioIndustry Association
BioIndustry Association is the trade association for innovative enterprises in the UK's bioscience sector. Established in 1989, our mission is to encourage and promote a thriving, financially sound sector of the UK economy, built upon developments across the biosciences. We seek to create economic growth, increase employment opportunities, and expand the skills base.